Nick Pavlakis
Associate Professor
Medical Oncology
Northern Cancer Institute
Australia
Biography
A/Prof Nick Pavlakis underwent undergraduate medical training at the University of NSW and graduated in 1991. He underwent general medical training and subsequent advanced training in Medical Oncology at Royal North Shore Hospital, completing FRACP in 1997. He then spent 3 years completing a PhD in new cancer drug development involving an Australian developed anti-angiogenic compound PI-88 (Progen Industries and ANU); and a Masters of Clinical Epidemiology through the University of Sydney. He has worked in private oncology practice since 1998 and has been a practice member of the Northern Cancer Institute since 2001. He is current Chair of the Lung Cancer Group of the Clinical Oncologic Society for Australa (COSA), and is Regent for Australasia for the International Association for the Study of Lung Cancer (IASLC).
Research Interest
He is an academic medical oncologist, having published journal manuscripts in his interest areas (lung cancer, mesothelioma, NETS, kidney cancer, gastric cancer, colorectal cancer and bisphosphonate therapy, is conducting ongoing collaboratve clinical research ((Australasian Gastro-intestinal Trials Group (AGITG), ALTG, Australia and NZ Urologic and Prostate Cancer Trials Group (ANZUP)) and translational research with the Bill Walsh Cancer Research Laboratories/Kolling Institute.
Publications
-
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
-
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: proposal for a Novel Grading Scheme with Prognostic Significance.
-
Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis.
